Viracta Therapeutics Probability of Future Pink Sheet Price Finishing Over 0.0301
| VIRXDelisted Stock | USD 0.03 0 7.38% |
Viracta |
Viracta Therapeutics Target Price Odds to finish over 0.0301
The tendency of Viracta Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.03 | 90 days | 0.03 | close to 99 |
Based on a normal probability distribution, the odds of Viracta Therapeutics to move above the current price in 90 days from now is close to 99 (This Viracta Therapeutics probability density function shows the probability of Viracta Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 2.65 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Viracta Therapeutics will likely underperform. Additionally Viracta Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Viracta Therapeutics Price Density |
| Price |
Predictive Modules for Viracta Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Viracta Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Viracta Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Viracta Therapeutics is not an exception. The market had few large corrections towards the Viracta Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Viracta Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Viracta Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.99 | |
β | Beta against Dow Jones | 2.65 | |
σ | Overall volatility | 0.04 | |
Ir | Information ratio | -0.17 |
Viracta Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Viracta Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Viracta Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Viracta Therapeutics is not yet fully synchronised with the market data | |
| Viracta Therapeutics generated a negative expected return over the last 90 days | |
| Viracta Therapeutics has high historical volatility and very poor performance | |
| Viracta Therapeutics has some characteristics of a very speculative penny stock | |
| Viracta Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viracta Therapeutics currently holds about 83.14 M in cash with (39.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Viracta Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Viracta Pink Sheet often depends not only on the future outlook of the current and potential Viracta Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Viracta Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.6 M | |
| Cash And Short Term Investments | 53.7 M |
Viracta Therapeutics Technical Analysis
Viracta Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Viracta Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Viracta Therapeutics. In general, you should focus on analyzing Viracta Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Viracta Therapeutics Predictive Forecast Models
Viracta Therapeutics' time-series forecasting models is one of many Viracta Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Viracta Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Viracta Therapeutics
Checking the ongoing alerts about Viracta Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Viracta Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Viracta Therapeutics is not yet fully synchronised with the market data | |
| Viracta Therapeutics generated a negative expected return over the last 90 days | |
| Viracta Therapeutics has high historical volatility and very poor performance | |
| Viracta Therapeutics has some characteristics of a very speculative penny stock | |
| Viracta Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viracta Therapeutics currently holds about 83.14 M in cash with (39.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |